Stocks Higher as In...
Health Care: Drugs
Orexigen Therapeutics Inc. (OREX: NASDAQ)
$6.38 0.10 | 1.59%
06/18/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 78.33M | 101.75M | 24.93M | 37.66M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 138.89M | 148.72M | 94.87M | 93.69M |
| Property, Plant & Equipment, Gross | 1.96M | 2.14M | 2.28M | 2.24M |
| Accumulated Depreciation & Depletion | 1.88M | 1.70M | 1.38M | 912.00K |
| Property, Plant & Equipment, Net | 83.00K | 439.00K | 894.00K | 1.32M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 177.00K | 542.00K | 1.08M | 1.84M |
| Total Non-Current Assets | 260.00K | 981.00K | 1.98M | 3.16M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 139.15M | 149.70M | 96.85M | 96.85M |
| Accounts Payable | 3.81M | 1.53M | 3.11M | 4.71M |
| Short Term Debt | 0.00 | 0.00 | 2.42M | 6.38M |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 25.11M | 7.71M | 16.29M | 16.30M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 2.42M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 38.57M | 42.29M | 46.77M | 2.23M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 38.57M | 42.29M | 46.77M | 4.64M |
| Total Liabilities | 63.68M | 49.99M | 63.06M | 20.94M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 75.47M | 99.71M | 33.79M | 75.90M |
| Common Par | 84.00K | 61.00K | 48.00K | 47.00K |
| Additional Paid In Capital | 512.17M | 446.36M | 352.40M | 342.60M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -436.80M | -346.71M | -318.65M | -266.74M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 15.00K | -2.00K | -9.00K | -6.00K |
| Total Capitalization | 75.47M | 99.71M | 33.79M | 78.32M |
| Total Equity | 75.47M | 99.71M | 33.79M | 75.90M |
| Total Liabilities & Stock Equity | 139.15M | 149.70M | 96.85M | 96.85M |
| Total Common Shares Outstanding | 84.41M | 61.29M | 47.77M | 47.22M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 70.74M | 48.27M | 47.38M | 39.90M |
| Diluted Weighted Shares Outstanding | 70.74M | 48.27M | 47.38M | 39.90M |
| Number of Employees | 41 | 23 | 33 | 61 |
| Number of Part-Time Employees | 2 | 2 | 1 | 1 |
Portfolios with OREX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- User2012 picks 10/28/20121
- ContributorBreakout Stocks Of The Week...
- Usermy picks
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks Under-$10 Setting ...
Latest OREX Headlines from TheStreet
- Biotech Stock Mailbag: 2013 Clinical Trials Calendar 06.07.13 | 07:06 am
- Commit To Purchase Orexigen Therapeutics At $3, Earn 23.3% 05.23.13 | 02:05 pm
- 5 Stocks Under $10 Set to Soar 05.23.13 | 01:05 pm
- 8 Stocks Under $10 Moving Higher 02.28.13 | 11:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Two 01.08.13 | 11:01 am
- J.P. Morgan: Biotech Stocks Heading Higher in 2013 01.02.13 | 07:01 am
- Biotech Stock Mailbag: More Amarin, MannKind, Orexigen 11.02.12 | 07:11 am
- Vivus Weight-Loss Drug's Failing Math 10.31.12 | 01:10 pm
- 5 Stocks Poised for Breakouts 10.26.12 | 01:10 pm
- Orexigen Therapeutics' CEO Presents At Bank Of America Merrill Lynch Global Healthcare Conference - Special Call Transcript 09.13.12 | 12:09 pm
Press Releases for OREX
- SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Orexigen Therapeutics, Inc. - PR Newswire 05.07.13 | 11:05 am
- Orexigen Therapeutics To Host First Quarter 2013 Financial Results Conference Call And Webcast - PR Newswire 05.02.13 | 08:05 am
- Orexigen Therapeutics Commends The Campaign To End Obesity's Report On Long-term Returns Of Obesity Prevention Policies - PR Newswire 04.25.13 | 04:04 pm
- Orexigen CEO Michael Narachi Elected To PhRMA Board Of Directors - PR Newswire 04.22.13 | 08:04 am
- Orexigen Therapeutics To Host Full Year And Fourth Quarter 2012 Financial Results Conference Call And Webcast - PR Newswire 03.07.13 | 08:03 am
- Orexigen Therapeutics Announces Progress With FDA On A Faster Path To Resubmission Of The Contrave NDA - PR Newswire 01.07.13 | 08:01 am
- Orexigen Therapeutics Concludes Light Study Patient Screening, Expecting To Randomize Approximately 9,000 Patients, And Presents New Obesity Therapeutics Market Research - PR Newswire 12.18.12 | 08:12 am
- Orexigen Therapeutics To Host Analyst Day Event On December 18, 2012 - PR Newswire 12.04.12 | 08:12 am
- Orexigen Therapeutics Schedules November 7, 2012 Conference Call And Webcast Discussion Of Financial Results For The Third Quarter Ended September 30, 2012 - PR Newswire 10.31.12 | 08:10 am
- Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion Of Financial Results For The Second Quarter Ended June 30, 2012 - PR Newswire 07.31.12 | 04:07 pm
Partner Headlines for OREX
- Vivus And Anti-Obesity Sector Benefit From New Insurance Deal - Seeking Alpha 05.01.13 | 09:05 am
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Vivus Reports A Weak 1st Quarter For Qsymia - Seeking Alpha 11.08.12 | 09:11 am
- The right data is key to spotting trends - NASDAQ 09.21.12 | 02:09 pm
- Vivus Launches Obesity Drug Qsymia - Analyst Blog - NASDAQ 09.20.12 | 10:09 pm
- Vivus Launches Obesity Drug Qsymia - Analyst Blog - Zacks 09.20.12 | 06:09 pm
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Investing in Biotech Stocks? The Journey to Profits Requires a Good GPS - NASDAQ 08.31.12 | 04:08 pm
- Arena And Vivus Set To Dominate The Obesity Drug Market - Seeking Alpha 08.30.12 | 09:08 am
- Arena Cuts Loss, Sales Climb - Analyst Blog - Zacks 08.14.12 | 09:08 am
